StockData
ARS Pharmaceuticals, Inc. logo

ARS Pharmaceuticals, Inc. (SPRY) stock

SPRYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$3.69+0.04 (+1.10%)

Close on Nov 18, 2026Market cap $366.96MP/E –Yield –

ARS Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

ARS Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was -$196.60M. For fiscal 2025 it was -$171.21M, down 1418.5% from the year before. The highest annual figure on record is $12.99M in fiscal 2024.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$171.21M-1418.5%
FY2024Dec 31, 2024$12.99M–
FY2023Dec 31, 2023-$59.44M–
FY2022Dec 31, 2022-$40.28M–
FY2021Dec 31, 2021-$17.62M–
FY2020Dec 31, 2020-$32.11M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$60.93M–
Q1 FY2026Mar 31, 2026-$44.95M–
Q4 FY2025Dec 31, 2025-$43.49M-204.3%
Q3 FY2025Sep 30, 2025-$47.24M–
Q2 FY2025Jun 30, 2025-$39.64M–
Q1 FY2025Mar 31, 2025-$40.83M–
Q4 FY2024Dec 31, 2024$41.70M–
Q3 FY2024Sep 30, 2024-$14.61M–
Q2 FY2024Jun 30, 2024-$7.32M–
Q1 FY2024Mar 31, 2024-$6.79M–
Q4 FY2023Dec 31, 2023-$17.31M–
Q3 FY2023Sep 30, 2023-$12.81M–
Q2 FY2023Jun 30, 2023-$16.70M–
Q1 FY2023Mar 31, 2023-$12.62M–
Q4 FY2022Dec 31, 2022-$20.62M-172.0%
Q3 FY2022Sep 30, 2022-$5.71M–
Q2 FY2022Jun 30, 2022-$7.00M–
Q1 FY2022Mar 31, 2022-$6.95M–
Q4 FY2021Dec 31, 2021$28.66M–
Q3 FY2021Sep 30, 2021-$19.21M–
Q2 FY2021Jun 30, 2021-$14.84M–
Q1 FY2021Mar 31, 2021-$12.24M–
Q4 FY2020Dec 31, 2020-$11.34M–
Q3 FY2020Sep 30, 2020-$7.66M–
Q2 FY2020Jun 30, 2020-$5.45M–
Q1 FY2020Mar 31, 2020-$7.66M–

More ARS Pharmaceuticals figures

See a number that looks wrong?